Current and future use of angiotensin II receptor blockers in patients with COVID-19
No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within clinical trials. Patients who have been taking...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Izdatelstvo OKI
2020-10-01
|
| Series: | Качественная клиническая практика |
| Subjects: | |
| Online Access: | https://www.clinvest.ru/jour/article/view/521 |
| _version_ | 1797262061474938880 |
|---|---|
| author | A. V. Matveev V. A. Otdelenov D. A. Sychev |
| author_facet | A. V. Matveev V. A. Otdelenov D. A. Sychev |
| author_sort | A. V. Matveev |
| collection | DOAJ |
| description | No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within clinical trials. Patients who have been taking angiotensin II receptor blockers for approved indications should continue to do so. |
| first_indexed | 2024-04-24T23:51:07Z |
| format | Article |
| id | doaj.art-afa3c8b3fd624d6d950349880cbac44c |
| institution | Directory Open Access Journal |
| issn | 2588-0519 2618-8473 |
| language | Russian |
| last_indexed | 2024-04-24T23:51:07Z |
| publishDate | 2020-10-01 |
| publisher | Izdatelstvo OKI |
| record_format | Article |
| series | Качественная клиническая практика |
| spelling | doaj.art-afa3c8b3fd624d6d950349880cbac44c2024-03-14T18:09:09ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732020-10-0104S283110.37489/2588-0519-2020-S4-28-31505Current and future use of angiotensin II receptor blockers in patients with COVID-19A. V. Matveev0V. A. Otdelenov1D. A. Sychev2ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииNo scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within clinical trials. Patients who have been taking angiotensin II receptor blockers for approved indications should continue to do so.https://www.clinvest.ru/jour/article/view/521коронавирусблокаторы рецептора ангиотензина 2-го типаcovid-19 |
| spellingShingle | A. V. Matveev V. A. Otdelenov D. A. Sychev Current and future use of angiotensin II receptor blockers in patients with COVID-19 Качественная клиническая практика коронавирус блокаторы рецептора ангиотензина 2-го типа covid-19 |
| title | Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
| title_full | Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
| title_fullStr | Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
| title_full_unstemmed | Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
| title_short | Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
| title_sort | current and future use of angiotensin ii receptor blockers in patients with covid 19 |
| topic | коронавирус блокаторы рецептора ангиотензина 2-го типа covid-19 |
| url | https://www.clinvest.ru/jour/article/view/521 |
| work_keys_str_mv | AT avmatveev currentandfutureuseofangiotensiniireceptorblockersinpatientswithcovid19 AT vaotdelenov currentandfutureuseofangiotensiniireceptorblockersinpatientswithcovid19 AT dasychev currentandfutureuseofangiotensiniireceptorblockersinpatientswithcovid19 |